Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Alzheimer's Disease
NCT06384378Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in Alzheimer's disease (AD), sponsored by Houston Methodist Research Institute. Started Mar 2023; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06384378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384378.